What is ALLO's dilution risk score?

ALLO currently has a DilutionScore of 34/100, indicating medium dilution risk. DilutionWatch monitors ALLO SEC filings in real-time, scanning EDGAR every 60 seconds for shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals.

What SEC filings does DilutionWatch track for ALLO?

DilutionWatch tracks 25 SEC filing types for ALLO including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect ALLO shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For ALLO, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for ALLO tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for ALLO. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

ALLO Dilution Risk Score: 34/100 (MEDIUM)

📊 Score Breakdown

📋 Offering Ability

42

💰 Cash Runway

25

📊 Float Risk

27

⚠️ Warrant Exposure

40

🔄Convertible Debt—

🌦️ Dilution Forecast

☀️

Clear

No significant dilution signals

13%

💰 Capital Raise 18%

• Active ATM program with $175M remaining capacity

🔄 Reverse Split 15%

• 52-week low $0.98 has breached $1

🔔 Track ALLO — Get forecast alerts →

💹 Market Data

Market Cap$748.99M

Shares Outstanding345.15M

Float269.64M

Cash$314.30M

Debt$81.05M

Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 26.1% shares (2026Q1 vs prior)

208 institutional holders · 207.61M shares

#1 Pfizer Inc 22.03M shares

#2 BlackRock, Inc. 19.09M shares

#3 TPG GP A, LLC 18.72M shares

+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest63.39M

Days to Cover5.1

% of Float23.5%

FINRA data as of Jun 30, 2026

👤 Insider Buy/Sell Ratio

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2020

4 INSIDER TRANSACTION Jul 06, 2026

4 INSIDER TRANSACTION Jun 23, 2026

Full SEC filing analysis available with free account →

📰 Recent News

Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial Exec Edge · Jun 30

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? Zacks · Jun 12

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases Exec Edge · Jun 09

📋 What This Means for ALLO Shareholders

Allogene Therapeutics, Inc. (ALLO) has a DilutionScore of 34/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

ALLO has an active ATM (at-the-market) program with $175.0M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event.

DilutionWatch tracks over 25 SEC filing types for ALLO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ALLO alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

How ATM Offerings Work →